CBO0 Stock Chart & Stats
€1.24
-€0.01(-0.80%)
At close: 4:00 PM EDT
€1.24
-€0.01(-0.80%)
Day’s Range― - ―
52-Week Range€1.23 - €5.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.99M
Enterprise Value€10.29
Total Cash (Recent Filing)€6.86M
Total Debt (Recent Filing)€7.85M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 16, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.53
Shares Outstanding5,611,403
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.15
Price to Sales (P/S)0.00
P/FCF Ratio-0.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.17Price Target Upside1123.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase II Overall Survival GainsRobust Phase II OS improvement is a durable clinical validation that materially de-risks the program versus competitors, strengthens regulatory and investigator confidence, and supports future partner interest and commercial potential if replicated in Phase III and final OS.
Phase III Enrollment & ExecutionConsistently faster-than-expected enrollment and rapid site activation indicate operational strength and execution capability, shortening development timelines, lowering per-patient trial friction, and increasing the probability of timely event-driven interims and regulatory milestones.
Structured $10M Financing, Limited DilutionA non-dilutive-lean financing structure preserves equity value and demonstrates access to capital markets. It extends near-term runway and supports ongoing Phase III activities while avoiding immediate heavy dilution, helping maintain alignment with long-term shareholders and partners.
Bears Say
No Meaningful Revenue; Persistent LossesAs a clinical-stage biotech, the company lacks recurring product revenue and posts large net losses. This structural lack of internal cash generation makes long-term program funding dependent on external capital, increasing dilution risk and limiting financial resilience over the medium term.
Weak Cash Flow With Rising BurnSustained negative operating and free cash flow, and a sharp TTM increase in outflows, signal intensifying funding needs. Higher burn reduces strategic optionality, pressures management to secure financing, and elevates the risk of unfavorable terms or program slowdowns if capital markets tighten.
Short Runway; Need For Additional CapitalA limited runway into late 2026 creates execution risk for the pivotal Phase III program. Dependence on near-term fundraising increases the chance of financing-related delays, interruptions to enrollment or manufacturing, or concessions to partners that could erode long-term upside.
Imunon News
CBO0 FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was €1.23 and its highest was €5.50 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is €7.99M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is Nov 16, 2026 which is in 91 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Aug 11, 2026. The company reported -€0.467 earnings per share for the quarter, beating the consensus estimate of -€0.75 by €0.284.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.53.
How many shares outstanding does Imunon have?
Imunon has 5,611,403 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -€0.467 in its last earnings report, beating expectations of -€0.75. Following the earnings report the stock price went up 1.55%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in DE:CBO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Imunon
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
CBO0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and translational momentum (robust Phase II OS gains, encouraging MRD signals, favorable safety) and operational execution (enrollment outperforming assumptions, cost discipline, recent financing), balanced against near-term financing needs and uncertainties tied to small MRD sample size and event-driven timing of Phase III interims. Overall the positives (clinical validation, enrollment traction, operational control) outweigh the negatives (short runway, need for additional capital, statistical limitations of MRD).View all DE:CBO0 earnings summariesCBO0 Stock 12 Month Forecast
Average Price Target
€15.17
▲(1123.49% Upside)